Sunday, August 1, 2021

FLCCC ALLIANCE

 

-->
  • HOME
  • IVERMECTIN IN COVID-19

Ivermectin in COVID-19

We regard ivermectin as a core medication in the prevention and treatment of COVID-19. For comprehensive information on ivermectin please refer to our  Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 and the included references.

For questions about the safety of this medicine, you can read the expert review of over 350 articles on the medical safety profile of ivermectin that was conducted by a toxicologist for Medincell, which reported that “No safety concern was anticipated that would prevent health authorities from assessing the use of Ivermectin against COVID-19.” The review is available at  www.medincell.com/ivermectin

A more recent paper,  Meta-analysis of Randomized Trials of Ivermectin to treat SARS-CoV-2 Infection was accepted for publication July 6, 2021, by Oxford University Press on behalf of the  Infectious Diseases Society of America. This study was done by Dr. Andrew Hill and the team that researched ivermectin’s efficacy in COVID-19 treatment for the WHO.  The data is overwhelmingly positive and was discussed in detail by Dr. Pierre Kory on the FLCCC’s July 7, 2021, Weekly Update.  Another recent paper,  Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines was published online June 17, 2021, by the American Journal of Therapeutics. It concludes, “Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.”

These pages contain the scientific rationale that justifies the use of ivermectin in COVID-19.

For PATIENTS AND RELATIVES, please review our  HELP PAGES. There you can find information on how to find physicians that prescribe ivermectin as well as information you can share with your primary care physician in the event they have not yet been made aware of the current evidence in support of ivermectin’s efficacy in COVID-19 prevention and treatment.

Ivermectin is a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases. It is one of the safest drugs known. It is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and has won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world. Our medical discovery of a rapidly growing published medical evidence base, demonstrating ivermectin’s unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted our team to use ivermectin for prevention and treatment in all stages of COVID-19. Ivermectin is not yet FDA-approved for the treatment of COVID-19, but on Jan 14, 2021, the NIH changed their recommendation for the use of ivermectin in COVID-19 from “against” to “neutral”. (see our  press release).

In March 2020 we created our life-saving  MATH+ Hospital Treatment Protocol for COVID-19, which is intended for hospitalized patients. In October 2020 we developed the  I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19, which is designed for use as a prophylaxis and in early outpatient treatment, for those who test positive for COVID-19. The protocols complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All the component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles. Both protocols are  available in several languages.

Recent studies and clinical trials on ivermectin

Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial can be found at the following link: https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1

For an up-to-date overview of all published studies on ivermectin in the treatment and prevention of COVID-19 we recommend visiting  c19ivermectin.com; in addition, a meta-analysis of all studies can be found at  ivmmeta.com (constantly updated).

A majority of the studies (until January 12, 2021) were included in our comprehensive  Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19, and a brief summary of the studies at that time can be found in the accompanying  One-page summary of the scientific review on ivermectin.

Update: The FLCCC Alliance’s “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19” has been peer-reviewed, accepted, and published on May 1, 2021, in the  American Journal of Therapeutics!

Summary of studies on the use of ivermectin in COVID-19:

Source: Database of all ivermectin COVID-19 studies – www.c19ivermectin.com – (constantly updated)

 

Source: Global ivermectin adoption for COVID-19 – ivmstatus.com (constantly updated)

Further information

Please also regard our  Videos & Tutorials section.

FLCCC Alliance review on ivermectin in COVID-19

Page 1 / 30
Zoom 100%

 Download as PDF

Posted by at

1 comment:

Steven Rivera said...

If you’ve at any factor had an adversarial reaction to Tadalafil 60 mg or any of the drugs’s extra fixings, don’t put it to use.
Kids ought not to use Tadarise. Even even though there is no conclusive evidence that Tadarise is risky to women, it's miles wiser to avoid this as it changed into made basically for men. Kids and minors ought not to make use of Tadarise.

December 12, 2021 at 3:06 AM

Post a Comment

Subscribe to: Post Comments (Atom)